contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


revenio-group-corporations-financial-reporting-and-annual-general-meeting-in-2026

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Revenios omsætning i dag til en stigende kurs er mangedoblet i forhold til det normale. De kloge ved, det gør jeg ikke…

Omkostningerne ved engangsudstyr blev undersøgt i en amerikansk undersøgelse, bl.a. for så vidt angår sensorer til rebound-tonometri. Dataene er baseret på en klinik med 80.000 patientbesøg om året. Omkostningerne til sensorerne blev estimeret for forskellige perioder, f.eks. var udgiften for en toårig periode 118.000 dollars. Mon ikke omkostningerne til sensorerne er af samme størrelsesorden hos Reve og konkurrenterne?                   PubMed              Costs Associated With the Use of Disposable Gonioscopy Lenses and Tonometry...    A widespread transition from reusable to disposable tonometry and gonioscopy equipment was associated with an additional cost of $965,161 over a 10-year period at a single institution.

op-media.fi – 14 Oct 25              Osakkeiden top 10 – Nämä ovat ammattilaisten valinnat pitkän aikavälin...    Asiantuntijat listasivat kotimaiset yhtiöt, joilla on edellytyksiä pitkän aikavälin menestykseen.                             Revenio nævnt i stærkt selskab. Når der tales om køb, ville det være godt at vide, hvordan tidligere køb skrider frem. Forhåbentlig har de trods alt været succesrige, selvom der ikke er set meget.

I de seneste kvartaler har der været engangsudgifter, som, læst mellem linjerne, har været relateret til potentielle virksomhedsovertagelser. Man kunne efterhånden ønske sig et opkøb i stil med Centervue, som kunne give virksomheden ny dynamik. Nu har der i flere år været moderat vækst i omsætningen, men til gengæld har resultatet været som en død hjertekurve. De tidligere mindre virksomhedsovertagelser har ikke været synlige i tallene udadtil, men har sikkert styrket virksomheden. Ligesom de seneste produktlanceringer er vigtige for virksomhedens konkurrenceevne og stabile vækst. Men heller ikke de har “sprængt banken” på en måde, der ville være synlig i væksttallene. Det er fint, at man undersøger mulighederne grundigt, så man ikke bare køber hvad som helst. Men man kunne godt ønske sig, at der snart blev fundet en perle, som kunne give Revenio ny energi. Det kunne også give nyt liv til kursen og vække interesse hos investorerne. En udvikling på -40% over de seneste 5 år vækker nok ikke den store interesse hos nye investorer.

Dyrere end guld?  Revenio-aktien er meget værdsat. DCF viser 28€, hvis driftsresultatet fordobles på 5 år.

Og @Juha_Kinnunen opdateret analyse, der er spænding tilbage for resten af året: Revenio Q3'25: Q4 ratkaisee tämänkin vuoden - Inderes Derudover fra Kauppalehtis hurtige nyheder: DNB Carnegie sænker Revenios kursmål til 29,00 euro (tidl. 29,80), gentager købsanbefalingen Lad os også tilføje dette fra samme kilde: Danske Bank sænker Revenios kursmål til 30,00 euro (tidl. 31,00), gentager købsanbefalingen

Revenio Group

Revenio Group Corporation | Stock Exchange Release | October 30, 2025 at 09:05:00 EETRevenio Group Corporation will publish the following financial reports in 2026:Financial Statements Bulletin...

<div class="mfn-header mfn-header-finland">Revenio Group Corporation | Stock Exchange Release | October 30, 2025 at 09:05:00 EET</div><div class="mfn-body">Revenio Group Corporation will publish the following financial reports in 2026:<ul><li>Financial Statements Bulletin for the year 2025 on Wednesday, February 11, 2026</li><li>Annual reporting package 2025 will be published at the latest during week 13 in 2026</li><li>Interim report 1-3/2026 on Tuesday, April 28, 2026</li><li>Half-year financial report 1-6/2026 on Thursday, August 6, 2026</li><li>Interim report 1-9/2026 on Thursday, October 29, 2026</li></ul>The financial statements bulletin, half-year report, and interim reports will be published at approximately 9.00 am Finnish time on the above dates. The Annual General Meeting is planned to be held on Thursday, April 15, 2026. The Board of Directors will convene the meeting.A shareholder who wishes to include an item on the agenda of the Annual General Meeting shall submit the request in writing to the company's Board of Directors by February 23, 2026. Such requests, including the reasoning or a resolution proposal, can be submitted to the address: Revenio Group Corporation / Board of Directors, Härkähaankuja 7, FI-01730 Vantaa, Finland.For further information, please contact Robin Pulkkinen, CFO, tel. +358 50&nbsp;505 9932 <a rel="noopener" href="mailto:robin.pulkkinen@revenio.fi">robin.pulkkinen@revenio.fi</a>Distribution Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Key media <a rel="noopener" href="http://www.reveniogroup.fi/en">www.reveniogroup.fi/en</a>Revenio Group in brief Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.In 2024, the Group’s net sales totaled EUR 103.5 million, with an operating profit of EUR 25.0 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/522ef875-316e-4741-a1d9-5617e3f5724e/revenio-group-corporations-financial-reporting-and-annual-general-meeting-in-2026.pdf" class="mfn-generated mfn-primary">Revenio Group Corporation’s financial reporting and Annual General Meeting in 2026</a></div>